Abdul Rehman Farooq

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Spring Holter · 1 shared paper, 2025 · strength 0.17
   • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
2. Joanna M. Karasinska · 1 shared paper, 2025 · strength 0.17
   • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
3. Sandra Elisabeth Fischer · 1 shared paper, 2025 · strength 0.17
   • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
4. Janessa J. Laskin · 1 shared paper, 2025 · strength 0.17
   • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
5. Rachel Anne Goodwin · 1 shared paper, 2025 · strength 0.17
   • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
6. Robert C. Grant · 1 shared paper, 2025 · strength 0.17
   • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
7. Raymond Jang · 1 shared paper, 2025 · strength 0.17
   • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
8. Oliver F. Bathe · 1 shared paper, 2025 · strength 0.17
   • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
9. Michelle Chan‐Seng‐Yue · 1 shared paper, 2025 · strength 0.17
   • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
10. James Thomas Topham · 1 shared paper, 2025 · strength 0.17
    • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
11. Grainne Mary O'Kane · 1 shared paper, 2025 · strength 0.17
    • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
12. Jennifer Jane Knox · 1 shared paper, 2025 · strength 0.17
    • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
13. David F. Schaeffer · 1 shared paper, 2025 · strength 0.17
    • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
14. Steve Gallinger · 1 shared paper, 2025 · strength 0.17
    • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
15. Daniel John Renouf · 1 shared paper, 2025 · strength 0.17
    • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
16. Erica S. Tsang · 1 shared paper, 2025 · strength 0.17
    • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
17. Malcolm J. Moore · 1 shared paper, 2025 · strength 0.17
    • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
18. Faiyaz Notta · 1 shared paper, 2025 · strength 0.17
    • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
19. Kyaw Lwin Aung · 1 shared paper, 2025 · strength 0.17
    • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗
20. George Zogopoulos · 1 shared paper, 2025 · strength 0.17
    • Paper The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. DOI 10.1038/s41698-025-00888-8↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.